<DOC>
	<DOCNO>NCT00389831</DOCNO>
	<brief_summary>The main objective phase 2a proof-of-concept trial ass efficacy rotigotine nasal spray ascend dos subject idiopathic Restless Legs Syndrome .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Rotigotine Nasal Spray Acute Treatment RLS Symptoms</brief_title>
	<detailed_description>Each patient placebo rotigotine group perform Eligibility Assessment , well 4 treatment day subject perform repeat 'Suggested Immobilization Test ' ( SIT ) 30min pre-dose 4 hour post-dose period . During period severity RLS symptom leg assess subject use numeric symptom severity scale . In addition leg movement measure actigraphy ass Periodic Leg Movement Index Wakefulness ( PLMWI , PLM per hour ) . Subjects apply single dose treatment treatment day ( placebo nasal spray rotigotine nasal spray 3 ascending dos ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects idiopathic RLS , respond ongoing Ldopa treatment Patients secondary RLS clinically relevant concomitant diseases medical condition exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Rotigotine nasal spray</keyword>
	<keyword>Efficacy , safety tolerability</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>